IRIS
TISEO, Marcello
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.903
AS - Asia 11.572
EU - Europa 8.238
SA - Sud America 2.329
AF - Africa 692
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 35.761
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.596
SG - Singapore 5.260
CN - Cina 2.974
BR - Brasile 1.844
IT - Italia 1.753
IE - Irlanda 1.663
SE - Svezia 1.399
HK - Hong Kong 1.134
VN - Vietnam 943
DE - Germania 669
FI - Finlandia 623
NL - Olanda 527
ZA - Sudafrica 465
FR - Francia 277
RU - Federazione Russa 277
GB - Regno Unito 274
IN - India 261
TR - Turchia 227
AR - Argentina 197
AT - Austria 195
CA - Canada 148
UA - Ucraina 142
BD - Bangladesh 135
ID - Indonesia 111
MX - Messico 101
EC - Ecuador 94
PL - Polonia 79
CI - Costa d'Avorio 77
IQ - Iraq 75
CZ - Repubblica Ceca 73
BE - Belgio 71
JP - Giappone 64
PK - Pakistan 61
ES - Italia 59
KR - Corea 52
CO - Colombia 43
MA - Marocco 38
PY - Paraguay 37
UZ - Uzbekistan 35
VE - Venezuela 34
CL - Cile 33
IR - Iran 32
LT - Lituania 26
KE - Kenya 25
TN - Tunisia 25
AZ - Azerbaigian 23
PE - Perù 20
KZ - Kazakistan 19
EG - Egitto 18
JO - Giordania 17
SA - Arabia Saudita 17
UY - Uruguay 16
AU - Australia 15
ET - Etiopia 15
IL - Israele 15
RO - Romania 15
LU - Lussemburgo 14
BG - Bulgaria 13
NP - Nepal 13
CH - Svizzera 12
MY - Malesia 11
PA - Panama 11
AE - Emirati Arabi Uniti 9
AL - Albania 9
BO - Bolivia 9
OM - Oman 9
BH - Bahrain 8
HN - Honduras 8
BY - Bielorussia 7
CR - Costa Rica 7
DO - Repubblica Dominicana 7
SI - Slovenia 7
SN - Senegal 7
TW - Taiwan 7
DK - Danimarca 6
DZ - Algeria 6
PS - Palestinian Territory 6
GR - Grecia 5
JM - Giamaica 5
KG - Kirghizistan 5
MK - Macedonia 5
PH - Filippine 5
RS - Serbia 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
AM - Armenia 4
BB - Barbados 4
HU - Ungheria 4
KW - Kuwait 4
LB - Libano 4
LK - Sri Lanka 4
MD - Moldavia 4
NO - Norvegia 4
PT - Portogallo 4
QA - Qatar 4
SV - El Salvador 4
XK - ???statistics.table.value.countryCode.XK??? 4
CY - Cipro 3
EE - Estonia 3
GT - Guatemala 3
Totale 35.701
Salva come PNG Salva come JPEG
Città #
Singapore 2.701
Chandler 1.715
Ashburn 1.704
Dublin 1.652
Dallas 1.279
Hong Kong 1.114
Beijing 818
Santa Clara 809
Boardman 519
Parma 461
Johannesburg 431
New York 370
Ann Arbor 363
Ho Chi Minh City 359
Princeton 358
Shanghai 318
Los Angeles 317
Munich 260
Dearborn 256
Hanoi 216
Nanjing 189
Des Moines 178
Helsinki 177
Wilmington 175
Moscow 163
Hefei 159
Vienna 159
São Paulo 150
Columbus 149
Milan 141
Izmir 139
Jacksonville 131
Bremen 101
Buffalo 100
Seattle 100
Bologna 95
The Dalles 95
Marseille 93
Jakarta 92
Jinan 86
Abidjan 77
Chicago 77
Rio de Janeiro 77
San Mateo 74
Nuremberg 68
Warsaw 64
Turku 63
Shenyang 62
Council Bluffs 60
Nanchang 60
Brussels 59
Redmond 59
Tianjin 58
London 56
Frankfurt am Main 55
Guangzhou 55
Kunming 54
Hebei 53
Denver 52
Tokyo 51
Fremont 50
Amsterdam 49
Brno 49
Belo Horizonte 48
Changsha 48
Toronto 47
Rome 45
Haiphong 44
Brooklyn 43
Chennai 43
Montreal 42
Houston 41
Phoenix 41
Atlanta 39
Bengaluru 39
Modena 39
Poplar 39
Pune 39
Curitiba 38
Norwalk 38
Seoul 37
San Francisco 33
Stockholm 32
Tashkent 32
Da Nang 31
Brasília 30
Verona 30
Baghdad 29
Boston 29
Porto Alegre 29
Quito 29
Falls Church 28
Jiaxing 28
Kocaeli 27
Redondo Beach 27
Dhaka 26
Guayaquil 26
Mexico City 26
Orem 26
Woodbridge 26
Totale 21.368
Salva come PNG Salva come JPEG
Nome #
LINFOCITI INFILTRANTI IL TUMORE, BAP-1, VEGFR-2 E IGF-1R NEL MESOTELIOMA PLEURICO MALIGNO 242
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 218
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 205
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 203
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 200
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 185
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 183
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 180
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 179
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 175
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 172
227P Sexual dimorphism in immune profile of early and advanced NSCLC 170
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 169
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 163
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 163
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 162
Characterization of gefitinib uptake in NSCLC cell lines 161
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 161
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 161
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 157
Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. 155
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 155
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 154
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 154
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 154
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 153
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 150
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 150
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 148
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 146
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 145
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 144
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 143
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 143
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 141
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 139
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 136
Advantages of multidetector row CT with multiplanar reformation in guiding percutaneous lung biopsies. 136
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 136
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 135
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 135
Neoplasie del polmone in Neoplasie del Distretto Toracico 135
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 135
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 134
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 133
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 133
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 133
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG CANCER (NSCLC 133
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 133
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 131
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 131
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 131
Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. 131
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 130
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 129
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 129
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 127
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 126
Curved Needles in CT-Guided Fine Needle Biopsies of Abdominal and Retroperitoneal Small Lesions 126
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 126
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 125
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 124
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 124
IASLC and WHO 2004 Grading System as Prognostic Factors in 492 Cases of Pulmonary Adenocarcinoma 124
Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience 124
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 123
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 123
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 121
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 121
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) 121
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 121
Multiple primary malignancies involving lung cancer: a single-center experience 121
SMO mutations confer poor prognosis in malignant pleural mesothelioma 121
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 120
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 120
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 120
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 119
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 119
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients 117
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 116
Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non small cell lung cancer(NSCLC) and fine needle aspirates from distant metastatic sites. 116
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 116
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 116
Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer 115
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 115
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 114
Semiautomatic analysis on computed tomography in locally advanced or metastatic non-small cell lung cancer: Reproducibility and Prognostic Significance of Unidimensional and 3-dimensional Measurements. 114
Expression levels of some antioxidant and epidermal growth factor genes on patients with early stage non small cell lung cancer 113
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 113
METACHRONOUS AND SYNCHRONOUS OCCURRENCE OF PRIMARY MALIGNANCIES IN PATIENTS WITH RESECTED NON SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE OBSERVATIONAL STUDY 113
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 113
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 112
TUMOR-INFILTRATING LYMPHOCYTES, PDL-1, BAP-1, VEGFR-2 AND IGF-1R EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA 112
Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine 112
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? 112
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 112
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 111
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. 111
Overexpression of microRNA‑486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting PIM1 111
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 111
Totale 13.833
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.379
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.379
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021754 0 0 0 0 0 85 71 67 175 75 201 80
2021/20221.834 56 32 60 101 51 34 304 136 82 41 134 803
2022/20236.278 806 675 367 428 518 681 70 410 1.991 28 219 85
2023/20242.925 134 199 90 89 288 652 209 199 127 195 256 487
2024/20259.002 220 570 662 514 913 879 452 376 1.079 913 757 1.667
2025/202612.129 1.715 1.799 2.944 2.197 3.262 212 0 0 0 0 0 0
Totale 36.515